Evidence map›Paper›PMID 41191713›Full record

ArticleJornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia2025

Treatment completion rates and adverse effects of three months of once-weekly isoniazid plus rifapentine for latent tuberculosis infection.

Tiene Heidy Maoski, Giovana Rodrigues Pereira, André Kulzer Santos, Raimunda Sinthia Lima de Braga, Marina Scheffer de Souza, Gean Souza Ramos, Allanamara Pereira Marinho, Renata Ullmann de Brito Neves, Denise Rossato Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tiene Heidy Maoski. Programa de Pós-Graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0009-0004-7302-3809
Giovana Rodrigues Pereira. Laboratório Municipal de Alvorada, Alvorada (RS) Brasil.ORCID http://orcid.org/0000-0001-6995-4046
André Kulzer Santos. Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0009-0001-7360-0600
Raimunda Sinthia Lima de Braga. Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0009-0002-6536-6188
Marina Scheffer de Souza. Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0009-0002-0274-3409
Gean Souza Ramos. Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0000-0002-9037-5708
Allanamara Pereira Marinho. Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0009-0008-4744-4799
Renata Ullmann de Brito Neves. Programa de Pós-Graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0000-0002-0437-4312
Denise Rossato Silva. Programa de Pós-Graduação em Ciências Pneumológicas, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.ORCID http://orcid.org/0000-0003-0230-2734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePreventive treatment of active tuberculosis is one of the main strategies for reducing the incidence of tuberculosis. We sought to evaluate the rates of latent tuberculosis infection (LTBI) treatment completion with three months of once-weekly isoniazid plus rifapentine (3HP) and compare them with those for six to nine months of daily isoniazid (6H/9H).

methodsThis was a retrospective cross-sectional study. Consecutive patients undergoing LTBI treatment with 3HP or 6H/9H were included in the study. Treatment completion rates and adverse effects were analyzed.

resultsA total of 226 patients were included in the study: 113 in the 3HP group and 113 in the 6H/9H group. The frequency of adverse effects was not significantly different between the 3HP and 6H/9H groups. The 3HP group had a higher treatment completion rate (93.8%) than did the 6H/9H group (84.1%), the difference being significant.

conclusionsThe rates of LTBI treatment completion appear to be higher with 3HP than with 6H/9H. Health care professionals should be vigilant in managing adverse effects to further maximize LTBI treatment completion.

Indexed as

Antitubercular AgentsIsoniazidLatent TuberculosisRifampinAdultCross-Sectional StudiesDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRetrospective StudiesTime FactorsTreatment OutcomeYoung AdultAntitubercular AgentsIsoniazidRifampinrifapentine

Identifiers

PMID41191713
PMCPMC12602054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.